help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2002-0373
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, J.
Right arrow Articles by Lala, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, J.
Right arrow Articles by Lala, D. S.
Molecular Endocrinology 18 (1): 53-62
Copyright © 2004 by The Endocrine Society

Repression of p65 Transcriptional Activation by the Glucocorticoid Receptor in the Absence of Receptor-Coactivator Interactions

Jun Wu, Yu Li, Jessica Dietz and Deepak S. Lala

Department of Biochemistry and Molecular Biology, Pharmacia Corp., St. Louis, Missouri 63198

Address all correspondence and requests for reprints to: Deepak S. Lala, Molecular Sciences and Technologies, Ann Arbor Laboratories, Pfizer Inc., 2800 Plymouth Road, Ann Arbor, Michigan 48105. E-mail: deepak.s.lala{at}pfizer.com.

Glucocorticoids are among the most potent antiinflammatory agents, acting through the glucocorticoid receptor (GR) to suppress gene expression of a variety of cytokines. This appears to be via transcriptional interference (or transrepression) of key regulatory factors such as nuclear factor-{kappa}B and activator protein 1. Ligand-bound GR can also activate gene transcription (transactivation) via direct binding to glucocorticoid response elements. Transactivation by GR is potentiated by accessory coactivators such as steroid receptor coactivator 1 and peroxisome proliferator-activated receptor {gamma} coactivator 1, whereas the role of these proteins in transrepression is unclear.

Here, we show that GR can recruit several coactivator receptor interacting domains in a ligand-dependent manner. All interactions require the charge clamp defined by K579/E755, while a subset also requires a second charge clamp defined by R585/D590, within the GR ligand-binding domain. A point mutation, E755A, abolished all GR-receptor interacting domain interactions and led to a decrease in GR-mediated transactivation, but did not significantly affect GR-mediated transrepression of Gal4-p65 activity. Overexpression of a GR-interacting coactivator peptide blocked transactivation but did not affect transrepression of p65 or TNF{alpha}-induced IL-6 promoter activity. Finally, the GR antagonist RU486 did not recruit coactivators to GR but maintained the ability to transrepress p65 activity.

Our data suggest that different coactivators utilize distinct contact points to interact with GR. Although GR interactions with specific coactivators are critical for transactivation, they appear to be dispensable for at least certain aspects of GR-mediated transrepression of nuclear factor-{kappa}B. This is consistent with the notion that all GR- mediated repression is not intrinsically linked to activation and can be separated mechanistically.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR
Coregulators:   RIP140  |  TRAP220  |  PGC-1  |  TIF1α  |  CBP  |  p300  |  SRC-1  |  GRIP1  |  AIB1  |  ARA70  |  CIA
Ligands:   Dexamethasone  |  RU486



This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
K. Suino-Powell, Y. Xu, C. Zhang, Y.-g. Tao, W. D. Tolbert, S. S. Simons Jr., and H. E. Xu
Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol
Mol. Cell. Biol., March 15, 2008; 28(6): 1915 - 1923.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Newton and N. S. Holden
Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor?
Mol. Pharmacol., October 1, 2007; 72(4): 799 - 809.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
M Anttonen, H Parviainen, A Kyronlahti, M Bielinska, D B Wilson, O Ritvos, and M Heikinheimo
GATA-4 is a granulosa cell factor employed in inhibin-{alpha} activation by the TGF-{beta} pathway.
J. Mol. Endocrinol., June 1, 2006; 36(3): 557 - 568.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L.-G. Bladh, J. Liden, A. Pazirandeh, I. Rafter, K. Dahlman-Wright, S. Nilsson, and S. Okret
Identification of Target Genes Involved in the Antiproliferative Effect of Glucocorticoids Reveals a Role for Nuclear Factor-{kappa}B Repression
Mol. Endocrinol., March 1, 2005; 19(3): 632 - 643.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L.-G. Bladh, J. Liden, K. Dahlman-Wright, M. Reimers, S. Nilsson, and S. Okret
Identification of Endogenous Glucocorticoid Repressed Genes Differentially Regulated by a Glucocorticoid Receptor Mutant Able to Separate between Nuclear Factor-{kappa}B and Activator Protein-1 Repression
Mol. Pharmacol., March 1, 2005; 67(3): 815 - 826.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society